Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers U > Headlines for UCB SA > News item |
UCB price target upped by Merrill Lynch
UCB was reiterated by Merrill Lynch analyst Erica Whittaker at a buy rating, and the price target on the stock was raised to €48.00 per share following positive top line results for its drug Cimzia in Crohn's disease. UCB shares Wednesday rose €2.89, or 6.98%, at €44.30 on volume of 1,263,018 shares versus the three-month running average of 246,164 shares.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.